Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end‐stage liver disease: Analysis of data from the Hepa‐C registry
-
- Carlos Fernández Carrillo
- Liver Unit,Hospital Universitario Puerta de Hierro‐Majadahonda,IDIPHIM, CIBERehd, Majadahonda,Madrid,Spain
-
- Sabela Lens
- Liver Unit,Hospital Clínic de Barcelona, University of Barcelona,IDIBAPS, CIBERehd,Barcelona,Spain
-
- Elba Llop
- Liver Unit,Hospital Universitario Puerta de Hierro‐Majadahonda,IDIPHIM, CIBERehd, Majadahonda,Madrid,Spain
-
- Juan Manuel Pascasio
- Department of Gastroenterology,Hospital Universitario Virgen del Rocío,IBIS, CIBERehd,Sevilla,Spain
-
- Javier Crespo
- Gastroenterology and Hepatology Unit, Hospital Universitario Marqués de Valdecilla, Santander, IDIVAL,Universidad de Cantabria,Santander,Spain
-
- Juan Arenas
- Department of Gastroenterology,Hospital Universitario Donostia,San Sebastián,Spain
-
- Inmaculada Fernández
- Department of Gastroenterology,Hospital Universitario 12 de Octubre,Madrid,Spain
-
- Carme Baliellas
- Digestive Service, Hospital Universitario de Bellvitge,L'Hospitalet de Llobregat,Barcelona,Spain
-
- José Antonio Carrión
- Liver Section, Gastroenterology Department,Hospital del Mar,IMIM,Barcelona,Spain
-
- Manuel de la Mata
- Hepatology & Liver Transplant Unit,Hospital Universitario Reina Sofía,IMIBIC, CIBERehd,Córdoba,Spain
-
- Maria Buti
- Liver Unit,Hospital Universitario Vall d'Hebrón,CIBERehd,Barcelona,Spain
-
- Lluís Castells
- Liver Unit,Hospital Universitario Vall d'Hebrón,CIBERehd,Barcelona,Spain
-
- Agustín Albillos
- Gastroenterology and Hepatology Department, Hospital Universitario Ramón y Cajal,University of Alcalá, IRYCIS, CIBERehd,Madrid,Spain
-
- Manuel Romero
- Digestive Diseases Unit,Hospital Universitario Virgen de Valme,CIBERehd,Sevilla,Spain
-
- Juan Turnes
- Department of Gastroenterology,Complejo Hospitalario Universitario de Pontevedra and IISGS,Pontevedra,Spain
-
- Clara Pons
- Digestive Service,Hospital General Universitario de Castellón,Castellón de la Plana,Spain
-
- José María Moreno‐Planas
- Department of Gastroenterology,Complejo Hospitalario Universitario de Albacete,Albacete,Spain
-
- José Javier Moreno‐Palomares
- Internal Medicine,Hospital General de Segovia,Segovia,Spain
-
- Conrado Fernández‐Rodriguez
- Department of Gastroenterology,Hospital Universitario Fundación Alcorcón,Alcorcón,Madrid,Spain
-
- Javier García‐Samaniego
- Liver Unit,Hospital Universitario La Paz,CIBERehd, IdiPAZ,Madrid,Spain
-
- Martín Prieto
- Servicio de Medicina Digestiva, Unidad de Hepatología,Hospital Universitari i Politècnic La Fe and CIBERehd,Valencia,Spain
-
- Miguel Fernández Bermejo
- Digestive Service,Hospital San Pedro de Alcántara,Cáceres,Spain
-
- Javier Salmerón
- Digestive Service,Hospital Universitario San Cecilio,CIBERehd,Granada,Spain
-
- Ester Badia
- Digestive Service,Hospital Universitario de Burgos,Burgos,Spain
-
- Magdalena Salcedo
- Liver Unit,Hospital General Universitario Gregorio Marañón,IiSGM,Madrid,Spain
-
- José Ignacio Herrero
- Liver Unit,Clínica Universitaria de Navarra,IdiSNA, CIBERehd,Pamplona,Spain
-
- Rafael Granados
- Internal Medicine Service,H. U. de Gran Canaria Dr. Negrín,Las Palmas de Gran Canaria,Spain
-
- Michel Blé
- Servidigest Clinic of Barcelona,Spain
-
- Zoe Mariño
- Liver Unit,Hospital Clínic de Barcelona, University of Barcelona,IDIBAPS, CIBERehd,Barcelona,Spain
-
- José Luis Calleja
- Liver Unit, Hospital Universitario Puerta de Hierro‐Majadahonda,Universidad Autónoma de Madrid and CIBERehd,Madrid,Spain
抄録
<jats:p>Direct‐acting antiviral agents (DAAs) are highly effective and well tolerated in patients with chronic hepatitis C virus infection, including those with compensated cirrhosis. However, fewer data are available in patients with more advanced liver disease. Our retrospective, noninterventional, national, multicenter study in patients from the Spanish Hepa‐C registry investigated the effectiveness and safety of interferon‐free DAA regimens in patients with advanced liver disease, including those with decompensated cirrhosis, in routine practice (all currently approved regimens were registered). Patients transplanted during treatment or within 12 weeks of completing treatment were excluded. Among 843 patients with cirrhosis (Child‐Turcotte‐Pugh [CTP] class A, n = 564; CTP class B/C, n = 175), 90% achieved sustained virologic response 12 weeks after treatment (SVR12). Significant differences in SVR12 and relapse rates were observed between CTP class A and CTP class B/C patients (94% versus 78%, and 4% versus 14%, respectively; both <jats:italic toggle="yes">P</jats:italic> < 0.001). Serious adverse events (SAEs) were more common in CTP class B/C versus CTP class A patients (50% versus 12%, respectively; <jats:italic toggle="yes">P</jats:italic> < 0.001). Incident decompensation was the most common serious adverse event (7% overall). Death rate during the study period was 16/843 (2%), significantly higher among CTP class B/C versus CTP class A patients (6.4% versus 0.9%; <jats:italic toggle="yes">P</jats:italic> < 0.001). Baseline Model for End‐Stage Liver Disease (MELD) score alone (cut‐off 18) was the best predictor of survival. <jats:italic toggle="yes">Conclusion</jats:italic>: Patients with decompensated cirrhosis receiving DAAs present lower response rates and experience more SAEs. In this setting, a MELD score ≥18 may help clinicians to identify those patients with a higher risk of complications and to individualize treatment decisions. (H<jats:sc>epatology</jats:sc> 2017;65:1810‐1822).</jats:p>
収録刊行物
-
- Hepatology
-
Hepatology 65 (6), 1810-1822, 2017-04-28
Ovid Technologies (Wolters Kluwer Health)